SGFG
BTAI icon

Silver Grove Financial Group’s BioXcel Therapeutics BTAI Stock Holding History

Silver Grove Financial Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$468 Sell
331
-3
-0.9% -$4 ﹤0.01% 2091
2026
Q1 		$447 Buy
+334
New +$550 ﹤0.01% 485

Other funds holding BTAI

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFA
Oaktree Fund Advisors Los Angles, California $57.8M AUM 67.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Silver Grove Financial Group's BTAI Position: Q2 2026 in Review

Silver Grove Financial Group reduced its BioXcel Therapeutics (BTAI) stake by 0.9% in Q2 2026, selling an estimated $4 and leaving 331 shares worth $468. The position accounts for ﹤0.01% of the portfolio, ranked #2091.

Silver Grove Financial Group first reported a position in BTAI in Q1 2026 and has held it in 2 quarters since. 46 funds tracked by Wall St. Rank hold BTAI as of Q2 2026.

  • Silver Grove Financial Group held 331 shares of BioXcel Therapeutics worth $468 as of Q2 2026.
  • Silver Grove Financial Group sold 3 BioXcel Therapeutics shares in Q2 2026, an estimated $4.
  • BioXcel Therapeutics made up ﹤0.01% of Silver Grove Financial Group's portfolio in Q2 2026, its #2091 holding.
  • Silver Grove Financial Group first reported a position in BioXcel Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 46 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q2 2026.

Based on Silver Grove Financial Group's 13F filing for Q2 2026, filed 13 Aug 2026.